Full programme

Session A.02: Epidemiology & Burden of Disease
Wednesday 3 May 2017 14:00 - 15:45

Chairs: Shannon Ross & Marianne Leruez-Ville

14:00 - 14:20
LATE BREAKER: A phase II Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Reactivation in Acute Critical Illness [‘GRAIL’ Study] Michael Boeckh, Head, Infectious Disease Sciences Program University of Washington, Seattle, United States of America
14:20 - 14:45
Invited Lecture: Congenital CMV infection: can we predict long-term outcome? Ann Vossen, Clinical Virologist Leiden University Medical Center , Leiden, Netherlands
14:45 - 15:00
Neuroimaging findings as potential predictors of adverse outcomes in asymptomatic congenital CMV infection (cCMV) identified at birth Aparecida Yulie Yamamoto Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil
15:00 - 15:15
Outcomes From a State-wde Hearing-Targeted Cytomegalovirus Screening Program Albert Park University of Utah, Salt Lake City, United States of America
15:15 - 15:45
Infectious Reactivation of Cytomegalovirus Explaining Age- and Sex-Specific Patterns of Seroprevalence Michiel Van Boven National Institute for Public Health and the Environment, Bilthoven, Netherlands
15:30 - 15:45
Increasing Awareness and Promoting Strategies for Prevention of Congenital Cytomegalovirus Infection (cCMV) Among Young Pregnant Women Karen Fowler University of Alabama at Birmingham, Birmingham, United States of America
CMV 2017: the 6th International congenital CMV conference/16th International CMV/betaherpesvirus workshop in 2017<